Abstract: Novel absorbable foams, lyophilizing solutions, and lyophilizing and annealing processes are disclosed. The foams are made from copolymers of glycolide and epsilon-caprolactone. The foams are useful in or as implantable medical devices.

Abstract: Novel absorbable foams, lyophilizing solutions, and lyophilizing and annealing processes are disclosed. The foams are made from copolymers of glycolide and epsilon-caprolactone. The foams are useful in or as implantable medical devices.

Abstract: A buttress assembly is configured to temporarily adhere to a wet surgical stapler end effector. The buttress assembly includes a buttress body and a humidity tolerant adhesive material. The humidity tolerant adhesive material is applied to at least one side of the buttress body. The humidity tolerant adhesive material is configured to hold the buttress body to an underside of an anvil or a deck of a staple cartridge for at least five minutes in an environment of 100% relative humidity at approximately 37° C.

Abstract: A buttress is applied to an end effector of a surgical stapler. The buttress is loaded on a platform of a buttress applier cartridge. The end effector is closed upon the platform. An adhesive layer of the buttress secures the buttress to the end effector. The buttress is thus adhered to the end effector when the end effector is opened. The end effector is then actuated on tissue of a patient, thereby stapling the buttress to the tissue.

Abstract: Absorbable medical devices based on novel foams and films made from semi-crystalline, segmented copolymers of lactide and epsilon-caprolactone exhibiting long term absorption characteristics are disclosed. Also disclosed are methods of producing said foams and films, and useful polymer solutions.

Abstract: Novel absorbable foams, lyophilizing solutions, and lyophilizing and annealing processes are disclosed. The foams are made from copolymers of glycolide and epsilon-caprolactone. The foams are useful in or as implantable medical devices.

Abstract: A biocompatible meniscal repair device is disclosed. The tissue repair device includes a scaffold adapted to be placed in contact with a defect in a meniscus, the scaffold comprising a high-density, dry laid nonwoven polymeric material and a biocompatible foam. The scaffold provides increased suture pull-out strength.

Abstract: A biocompatible meniscal repair device is disclosed. The tissue repair device includes a scaffold adapted to be placed in contact with a defect in a meniscus, the scaffold comprising a high-density, dry laid nonwoven polymeric material and a biocompatible foam. The scaffold provides increased suture pull-out strength.

Abstract: A biocompatible meniscal repair device is disclosed. The tissue repair device includes a scaffold adapted to be placed in contact with a defect in a meniscus, the scaffold comprising a high-density, dry laid nonwoven polymeric material and a biocompatible foam. The scaffold provides increased suture pull-out strength.

Abstract: Tissue engineering devices for pelvic floor repair are disclosed. More specifically, tissue engineering devices made of an implant, having a central portion at least partially embedded within a nonwoven felt are disclosed.

Abstract: Compositions and methods for the treatment of tumors are disclosed. Specifically, the present invention provides hollow foam beads having a chemotherapeutic agent incorporated therein. A method of making such beads is disclosed. In addition, a method for treating a glioblastoma tumor and other types of tumors with the compressible hollow foam beads is disclosed.

Abstract: A barbed suture having a therapeutic agent.

Abstract: The present invention is directed to bone graft compositions suitable for administration to the body via a cannula, where the compositions contain mineralized collagen particles and a fluid biocompatible carrier having the mineralized collagen particles substantially uniformly distributed there through, which particles contain bound mineralized collagen fibrils substantially uniformly distributed there through and a binder for the fibrils; and to methods of making such particles.

Abstract: The present disclosure relates to bioprosthetics. For example, to the use of bioprosthetics for the repair and replacement of connective tissue.

Abstract: A biocompatible meniscal repair device is disclosed. The tissue repair device includes a scaffold adapted to be placed in contact with a defect in a meniscus, the scaffold comprising a high-density, dry laid nonwoven polymeric material and a biocompatible foam. The scaffold provides increased suture pull-out strength.

Abstract: Intra-operative coating of sutures with therapeutic proteins, particularly growth factors such as rhGDF-5. including contacting a suture to a device containing a therapeutic agent, methods of repairing soft tissue defects with coated sutures and composite sutures coated with therapeutic agents.

Abstract: Intra-operative coating of sutures with therapeutic proteins, particularly growth factors such as rhGDF-5. including contacting a suture to a device containing a therapeutic agent, methods of repairing soft tissue defects with coated sutures and composite sutures coated with therapeutic agents.

Abstract: Intra-operative coating of sutures with therapeutic proteins, particularly growth factors such as rhGDF-5. including contacting a suture to a device containing a therapeutic agent.

Abstract: The present invention is drawn to methods of preparing crosslinked collagen microspheres and microparticles, where a solution of soluble collagen in an aqueous acidic medium is combined with an emulsifying agent to form a first mixture of the soluble collagen solution and the emulsifying agent, the first mixture then is combined with a hydrophobic liquid under conditions effective to form water-in-oil emulsion of the hydrophobic liquid and the first mixture, the water-in-oil emulsion then is added to a buffered alcohol solution under conditions effective to form a dispersion of a continuous liquid phase and a dispersed solid phase of collagen fibers reconstituted from the soluble collagen solution, the liquid phase then is removed from the dispersion to provide collagen microspheres, the collagen microspheres then are crosslinked to form crosslinked collagen microspheres, and the crosslinked collagen microspheres then are optionally dried to form crosslinked collagen microparticles.